Analyst Reco. RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Market Closed - Nasdaq Other stock markets 02:00:00 07/05/2024 am IST			5-day change	1st Jan Change
8.28 ^USD	-0.60%		+5.08%	-66.68%

09/04	RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	CI
27/03	JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating	27/03	MT
UBS Downgrades RAPT Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $61	22/02	MT
Barclays Adjusts Price Target on RAPT Therapeutics to $13 From $35, Maintains Overweight Rating	21/02	MT
Leerink Partners Downgrades RAPT Therapeutics to Market Perform From Outperform, Price Target is $10	21/02	MT
HC Wainwright Downgrades RAPT Therapeutics to Neutral From Buy	21/02	MT
JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target is $15	21/02	MT
Stifel Cuts RAPT Therapeutics' Price Target to $33 From $40, Keeps Buy Rating	20/02	MT
Piper Sandler Cuts RAPT Therapeutics' Price Target to $18 From $31, Keeps Overweight Rating	20/02	MT
Cantor Fitzgerald Downgrades RAPT Therapeutics to Neutral From Overweight	20/02	MT
Evercore ISI Starts Coverage on RAPT Therapeutics With Outperform Rating	16/02	MT
Wolfe Research Starts RAPT Therapeutics With Outperform Rating, $39 Price Target	15/02	MT
RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC	03/11	CI
Berenberg Initiates RAPT Therapeutics With Buy Rating, Price Target is $34	14/23/14	MT
JPMorgan Adjusts Price Target on RAPT Therapeutics to $32 From $39, Maintains Overweight Rating	16/23/16	MT
Piper Sandler Adjusts Price Target on RAPT Therapeutics to $31 From $28, Maintains Overweight Rating	14/23/14	MT
Stifel Initiates Coverage on RAPT Therapeutics with Buy Rating, $40 Price Target	09/23/09	MT
Barclays Initiates RAPT Therapeutics With Overweight Rating, $35 Price Target	15/23/15	MT
HC Wainwright Adjusts Price Target on RAPT Therapeutics to $41 From $43, Keeps Buy Rating	12/23/12	MT
JPMorgan Adjusts Price Target on RAPT Therapeutics to $42 From $48, Maintains Overweight Rating	21/23/21	MT
Guggenheim Lowers Price Target on RAPT Therapeutics to $48 From $55, Maintains Buy Rating	15/23/15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Analyst Reco.

Filters